AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New Therapies Targeting Respiratory and Cardiovascular Diseases

 AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New Therapies Targeting Respiratory and Cardiovascular Diseases

AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New Therapies Targeting Respiratory and Cardiovascular Diseases

Shots:

  • AstraZeneca collaborates with Gatehouse Bio to explore new targets for respiratory and CV diseases utilizing Gatehouse Bio’s AI-powered sRNAlytics platform
  • The collaboration allows Gatehouse Bio to develop next-generation therapies and epitomizes its focus on Bio Hub Incubator. In 2018, Gatehouse Bio joined AstraZeneca’s Boston Bio Hub Incubator to accelerate their research and developed pipeline of RNA sequencing with biology-influenced ML algorithms after 18mos.
  • Gatehouse Bio’s sRNAlytics platform highlights molecular pathways of diseases via analyses of small RNA, then insights are converted to therapeutic targets and CDx

Click here to­ read full press release/ article | Ref: PRNewswire | Image: The Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post